How does Atorvastatin compare to PCSK9 inhibitors in managing lipid abnormalities, and which offers better results for high-risk cardiovascular patients?
Sahil KapoorExplorer
How does Atorvastatin compare to PCSK9 inhibitors in treating lipid abnormalities?
Share
Atorvastatin, a statin, effectively lowers LDL-C by inhibiting cholesterol synthesis. PCSK9 inhibitors, however, block a protein to enhance LDL receptor recycling, achieving even lower LDL-C levels. For high-risk patients, PCSK9 inhibitors often show superior outcomes in reducing cardiovascular events.